Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

REFERENCES

1. 1.↵
   1. Lee DM,
   2. Weinblatt ME

   . Rheumatoid arthritis. Lancet 2001;358:903–11.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Scott DL

   . Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl. 2004 Mar;69:55–65.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Welsing PM,
   2. van Gestel AM,
   3. Swinkels HL,
   4. Kiemeney LA,
   5. van Riel PL

   . The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Salaffi F,
   2. Carotti M,
   3. Gasparini S,
   4. Intorcia M,
   5. Grassi W

   . The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Lundkvist J,
   2. Kastang F,
   3. Kobelt G

   . The burden of rheumatoid arthritis and access to treatment: Health burden and costs. Eur J Health Econ 2008;8:S49–60.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mihara M,
   2. Kasutani K,
   3. Okazaki M,
   4. Nakamura A,
   5. Kawai S,
   6. Sugimoto M,
   7. et al.

   Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731–40.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Smolen JS,
   2. Beaulieu A,
   3. Rubbert-Roth A,
   4. Ramos-Remus C,
   5. Rovensky J,
   6. Alecock E,
   7. et al.

   Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Genovese MC,
   2. McKay JD,
   3. Nasonov EL,
   4. Mysler EF,
   5. da Silva NA,
   6. Alecock E,
   7. et al.

   Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Emery P,
   2. Keystone E,
   3. Tony HP,
   4. Cantagrel A,
   5. van Vollenhoven R,
   6. Sanchez A,
   7. et al.

   IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Jones G,
    2. Sebba A,
    3. Gu J,
    4. Lowenstein MB,
    5. Calvo A,
    6. Gomez-Reino JJ,
    7. et al.

    Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88–96.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Kremer JM,
    2. Blanco R,
    3. Brzosko S,
    4. Burgos-Vargas R,
    5. Halland AM,
    6. Vernon E,
    7. et al.

    Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Nishimoto N,
    2. Miyasaka N,
    3. Yamamoto K,
    4. Kawai S,
    5. Takeuchi T,
    6. Azuma J

    . Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008;68:1580–4.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Schiff MH,
    2. Kremer JM,
    3. Jahreis A,
    4. Vernon E,
    5. Isaacs JD,
    6. van Vollenhoven RF

    . Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13(R141):1–13.

    OpenUrl
14. 14.↵
    1. Genentech Inc

    . Actemra (tocilizumab) prescribing information. Genentech Inc. South San Francisco, CA: Genentech Inc.; 2010. [Internet. Accessed December 13, 2012.] Available from: www.gene.com/gene/products/information/actemra/pdf/pi.pdf
15. 15.↵
    1. Felson DT,
    2. Smolen JS,
    3. Wells G,
    4. Zhang B,
    5. van Tuyl LH,
    6. Funovits J,
    7. et al.

    American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Curtis JR,
    2. Xie F,
    3. Chen L,
    4. Spettell C,
    5. McMahan RM,
    6. Fernandes J,
    7. et al.

    The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346–51.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Solomon DH,
    2. Karlson EW,
    3. Rimm EB,
    4. Cannuscio CC,
    5. Mandl LA,
    6. Manson JE,
    7. et al.

    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Watson DJ,
    2. Rhodes T,
    3. Guess HA

    . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Solomon DH,
    2. Goodson NJ,
    3. Katz JN,
    4. Weinblatt ME,
    5. Avorn J,
    6. Setoguchi S,
    7. et al.

    Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608–12.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Fransen J,
    2. van Riel PL

    . DAS remission cut points. Clin Exp Rheumatol 2006;24:S29–32.

    OpenUrl